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Production of extended-spectrum 𝛽-lactamases (ESBLs) producing E. coli in animals and different methods of identifications from
Ado Ekiti, Ekiti State, Nigeria, were investigated.Three hundred and fifty fecal samples, collected from apparently healthy cattle and
pigs, were cultured and identified following standard procedures. ESBL phenotypic detection was carried out using combination
disc test, double disc synergism test, and ESBL brilliance agar screening. Molecular detection of TEM, SHV, and CTX-M genes
was carried out using standard molecular method. One hundred and fourteen E. coli isolates were recovered from the 350 samples
processed, out of which 72 (63.2%) isolates were positive for ESBLswithmultiple resistance to the antibiotics used. Eighty-one (71%)
isolates were positive for ESBL by combination disc test, 90 (78.9%) were positive for double disc synergism test, and 93 (81.6%)
were positive for ESBL brilliance agar. TEM and CTX-M genes were detected in 48 (42.1%) and 51 (44.7%) isolates, respectively.
SHV gene was not detected in any of the isolates while TEM and CTX-M were detected in 33 (28.9%) isolates. This study showed
high resistance of E. coli to antibiotics, particularly to the third generation cephalosporins. Regular monitoring and regulated use
of antibiotics in livestock should be encouraged.
1. Introduction
Production of extended-spectrum 𝛽-lactamases (ESBLs) is
the most common mechanism of resistance to third-gen-
eration cephalosporins among Enterobacteriaceae includ-
ing Klebsiella pneumoniae and Escherichia coli [1, 2]. ESBL
determinants have been detected not only in clinical iso-
lates but also in commensal bacteria from humans and
animals and in isolates from products of the food chain and
sewage, revealing distribution and suggesting the presence
of environmental reservoirs for these resistance determinants
[3, 4].
The increase in antimicrobial-resistant bacteria of animal
origin resembles the process in humans about two decades
ago [5]. Since the late 1990s, extended-spectrum 𝛽-lactamase
(ESBL) producing Enterobacteriaceae, in particular E. coli,
have emerged globally. Initially, ESBL producing bacteria
were only observed in human medical practice [6, 7] but
the recent observation of these bacteria, first in companion
animals and increasingly in livestock, has initiated moni-
toring studies focused on livestock [8]. ESBL producing E.
coli isolates are now being found in increasing numbers
of food-producing animals leading to the hypothesis that
animals might become infection sources or even reservoirs
(the natural persistent source of infection) contributing to the
spread of these bacteria [9].
Currently, there is paucity of information on ESBL pro-
ducing E. coli from animals and the possible contribution
of these resistant species to the ever growing antimicrobial
resistance observed in humans. The broad objective of this
study was to determine the occurrence of ESBL producing
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Escherichia coli in cattle and pigs in Ado Ekiti, SouthWestern
Nigeria.
2. Materials and Methods
2.1. Sample Collection. Three hundred and fifty fecal samples
were collected from cattle (𝑛 = 200) and pigs (𝑛 = 150).
Samples from apparently healthy cattle were collected from
the colon immediately after slaughtering the animal at the
abattoirs aseptically. Freshly passed feces from apparently
healthy pigs were collected into sterile capped universal
bottles with sterile spatula and were transported to the
laboratory immediately.
2.2. Isolation and Identification. Isolates were recovered from
the samples after culturing on modified selenite F and
incubated for 18–24 hours at 37∘C. The overnight incubated
liquid selective media were inoculated on Sorbitol Mac-
conkey Agar, Eosin Methylene Blue Agar, and Macconkey
Agar and incubated for 18–24 hours at 37∘C. Presumptive
characteristic E. coli isolates were identified and confirmed
using arrays of biochemical tests and API 20 E multitest
systems (bioMe´rieux, France). The study was carried out
in the Department of Medical Laboratory Science, ABUAD,
Ado Ekiti, and the Department of Medical Microbiology
and Parasitology LAUTECH, Osogbo, between February and
November 2014.
2.3. Susceptibility Test. Antimicrobial susceptibility of pure
colonies to Ampicillin (10 𝜇g), Amoxicillin (25𝜇g), Aug-
mentin (AUG) (30𝜇g), Cefotaxime (CTX) (30 𝜇g), Cef-
tazidime (CAZ) (30 𝜇g), Cefuroxime (CXM) (30 𝜇g), Cipro-
floxacin (CPX) (10 𝜇g), Cefixime (CXM) (5𝜇g), Cefpo-
doxime (CP) (10 𝜇g), Ofloxacin (5 𝜇g), Imipenem (10𝜇g),
Tetracycline (30 𝜇), Gentamicin (GEN) (10 𝜇g), Streptomycin
(STR) (10 𝜇g), Erythromycin (ERY) (10 𝜇g), Chlorampheni-
col (CHL) (25𝜇g), Cloxacillin (5 𝜇g), Nitrofurantoin (NIT),
and Cotrimoxazole (STX) (25𝜇g) was determined and inter-
preted by the disc diffusion method following the guidelines
of Clinical Laboratory Standard Institute [10].
2.4. Detection of Extended-Spectrum 𝛽-Lactamase (ESBL)
2.4.1. Cefpodoxime and Cefpodoxime-Clavulanate (Combi-
nation Disc Screening). Cefpodoxime and Cefpodoxime-
clavulanate (Oxoid, Basingstoke, UK) discs were applied on
freshly prepared Muller Hinton agar and the plates were
incubated aerobically at 37∘C. A final measurement of the
zone of inhibitionwasmade after overnight incubation. ESBL
producers were defined as having a differential zone diameter
of ≥+5mm (Cefpodoxime-clavulanate zone − Cefpodoxime
zone).
2.5. Double Disc Diffusion Test. A Ceftazidime 30 𝜇g disc
and Cefotaxime 30 𝜇g disc with Amoxicillin/clavulanic acid
20/10 𝜇g (Oxoid, UK) were placed in the center 20mm
apart and incubated at 37∘C for 18–20 hours [11]. ESBL
production was inferred when the zone of inhibition around
Table 1: Distribution of gram negative organisms isolated from
cattle and pigs.
Number
of
samples
Proteus spp. E. coli Pseudomonas spp. Klebsiella spp.
Cattle 21 79 84 125
Pigs 10 35 45 70
Total 31 114 129 195
the Ceftazidime and Cefotaxime discs was expanded by the
presence of clavulanate by ≥5mm.
2.6. ESBL Brilliance Agar. Oxoid ESBL brilliance agar
was inoculated according to manufacturer’s instructions.
Plates were inoculated with 1 𝜇L (a standard loopful) of a
0.5McFarland standard suspension of E. coli. Subsequently
they were incubated aerobically at 35 to 37∘C for 18 to 24
hours in an inverted position and presumptive ESBL E.
coli were identified based on color production. Escherichia
coli produced blue/pink coloration following 24–48 hours
of incubation. The reference E. coli strain ATCC25922 was
inhibited and was used as negative control.
2.7. Polymerase Chain Reaction to Detect bla Genes. The
DNA of the ESBL confirmed isolates was extracted separately
using a DNA extraction kit (Biospin plasmid extraction,
Bioflux, Japan). According to previously published work,
PCR was used to detect 𝑏𝑙𝑎TEM, 𝑏𝑙𝑎CTX-M, and 𝑏𝑙𝑎SHV genes
using specific primers [12]. Routine reactionswere performed
using the PCR master mix containing 3 𝜇L deoxynucleoside
triphosphate (dNTPs), 4 𝜇L ×10 Tris EDTA buffer, 0.2 𝜇L
Thermus aquaticus (Taq) polymerase, 0.5 𝜇L MgCl
2
, 5 𝜇L
DNA lysates, 15.3 𝜇L of PCR water, and 1 𝜇L of forward
and reverse primers in a 30 𝜇L final reaction volume. Elec-
trophoresis was done using 1% Agarose.
2.8. Statistical Analysis. The sensitivities and specificities of
the tests were determined. Differences in sensitivity and
specificity of the tests were analyzed with the chi square test
and log linear analysis using the Statistical Package for Social
Sciences software (SPSS version 21).
3. Results
Table 1 shows the highest prevalence of Klebsiella spp. both
in cattle and in pigs showing 125 and 70, respectively, while
the least bacterial isolate was Proteus spp. with a prevalence
of 21 and 10 for cattle and pigs, respectively, and Escherichia
coli and Pseudomonas spp. were 114 and 129, respectively.
Table 2 shows the distribution and sources of fecal sam-
ples; female cow investigated was 73, while bull male was 127
and 10 large pigs were the least collected.
3.1. Antibiotic Susceptibility Patterns of E. coli Isolates. Table 3
shows the results of all the 114 E. coli isolates that were
subjected to antimicrobial testing and interpreted as resistant,
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Table 2: Distribution and sources of the fecal samples.
Cattle Pigs
Cow (female) 73
Soar (female) 135 (10 piglets)
Large white 65
Large black 10
Hampshire 45
Duroc 15
Bull (male) 127 Boar (male) 15
intermediate, and sensitive following the guidelines of Clini-
cal Laboratory Standard Institute [10]. The overall resistance
of the isolates to antibiotics shows that resistance to Penicillin
(PEN) (96%), Ampicillin (AMC) (89%), Amoxicillin (AMX)
(88%), Augmentin (AUG) (96%), Cefotaxime (CTX) (92%),
Cefuroxime (CPX) (83%), Cloxacillin (CXC) (84%), and
Cotrimoxazole (STX) (90%) was high while resistance to
Ciprofloxacin and Ofloxacin was low with 5% resistance
to these antibiotics. The isolates also showed considerable
resistance to Ampicillin, Tetracycline, Cotrimoxazole, and
Cephalosporins as shown in Table 3.
The number of isolates that showed resistance simultane-
ously to twelve (12) different antibiotics was 42 (37.8%) and
was highest among those isolates that demonstrated multiple
antibiotic resistance while only 6 (5.6%) isolates showed
resistance simultaneously to fifteen out of the 20 antibiotics
tested. All the 114 E. coli isolates showed resistance to at
least nine antibiotics. All isolates that were resistant to more
than two classes were identified asmultidrug resistant (MDR)
isolates and were selected for possible ESBL production
screening (Table 4).
3.2. Phenotypic Test. Figure 1 shows the results of the phe-
notypic tests used. Eighty-one (71%) isolates out of the
114 isolates were positive for combination disc test (Cef-
podoxime/clavulanic acid) as shown in the figure. There
was a significant association (𝑝 = 0.026) between Cef-
podoxime/clavulanic acid and the detection of ESBL genes
(CTX, SHV, and TEM). The sensitivity of the test was calcu-
lated using molecular detection as the gold standard was 89%
while specificity was 82%.The rate of false positive prediction
(1 − specificity) was 0.18 (18%). Double disc synergism
test using Cefotaxime/Ceftazidime/clavulanate substrate was
positive in 90 (78.9%) isolates out of the 114 isolates.Therewas
an association between this phenotypic test and the detection
of CTX-M genes (𝑝 = 0.025) and TEM genes (𝑝 < 0.001)
(Table 5). The sensitivity of the test was 80% while specificity
was 70%.The rate of false positive prediction (1 − specificity)
was 30%. ESBL brilliance agar was positive in 93 (81.57%)
isolates. There was a significant association (𝑝 < 0.001)
in the result obtained by Cefpodoxime/clavulanic acid and
ESBL brilliance agar. The sensitivity of the test was 79% and
specificity was 67% while rate of false positive prediction was
33%.
3.3. Detection of ESBLGenes. Themolecular characterization
of resistant gene of theE. coli isolates using PCRwas analysed.
SHV showed no specific amplification and thus was not
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Figure 1: Representation of phenotypic detection of ESBL.
detected in any of the samples. A total of 51 (44.7%) isolates
showed detectable CTX-M genes while TEM genes were
present in 48 (42%) E. coli isolates.
4. Discussion and Conclusion
Antibiotic resistance has continued to constitute serious
problems not only in human medicine but also in animal
husbandry, livestock management, and veterinary medicine
[13, 14].
In this study, severalmethods of detectionwere employed
as previously reported methods of ESBLs detection. The
major finding in the present study is the presence of multiple
drug resistant commensal E. coli in animals to commonly
used antibiotics such as Penicillin (96%), Augmentin (96%),
Cefotaxime (92%), Ceftazidime (58%), Cefuroxime (83%),
and Cotrimoxazole (STX) (90%). This observation reiterates
the finding in other studies that have reported antibiotic
resistance among bacteria especially E. coli isolated from
cattle and other animals is increasing at an alarming rate [15–
18]. In this study, susceptibility of all the isolates that showed
multiple resistance to a minimum of nine antibiotics was 3
(2.6%). 12 (10.5%) isolates were resistant to ten antibiotics,
6 (5.6%) isolates were resistant to 13 different antibiotics,
and 42 (36.8%) isolates were resistant to twelve antibiotics,
while 9 (7.9%) isolates were resistant to fifteen antibiotics.
This finding correlates with similar results obtained from
other studies that have reported some levels of multiple
antibiotic resistance by E. coli from cattle, meat products,
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Table 3: Antimicrobial sensitivity patterns of E. coli isolates based on the classes of antibiotics tested.
Class/antibiotics Number of resistant isolates (%) Number of intermediate isolates (%) Number of sensitive isolates (%)
𝛽-lactams
Penicillin 110 (96%) 04 (4%) —
Amoxicillin 100 (88%) 14 (12%) —
Ampicillin 102 (89%) 12 (11%) —
Augmentin 110 (96%) 04 (4%) —
Ceftazidime 66 (58%) 27 (24%) 21 (18%)
Cefotaxime 105 (92%) 9 (8%) —
Cefixime 45 (39%) 42 (37%) 27 (24%)
Cefuroxime 95 (83%) 10 (9%) 8 (7%)
Cefpodoxime 66 (58%) 06 (5%) 42 (37%)
Tetracycline 100 (88%) 9 (8%) 4 (4%)
Erythromycin 94 (82%) 15 (13%) 5 (4%)
Streptomycin 90 (79%) 15 (13%) 9 (8%)
Gentamicin 56 (49%) 03 (3%) 55 (48%)
Ciprofloxacin 6 (5%) 6 (5%) 102 (90%)
Ofloxacin 6 (5%) 5 (4%) 103 (90%)
Cloxacillin 96 (84%) 18 (16%) —
Cotrimoxazole 102 (90%) 12 (10%) —
Nitrofurantoin — 12 (11%) 102 (89%)
Chloramphenicol 105 (92%) 9 (8%) —
Carbapenem
Imipenem — 5 (4%) 109 (96%)
Table 4: The frequency distribution of antibiotics and resistant
isolates.
Number of antibiotics Number of resistant isolates (%)
09 03 (2.6%)
10 12 (10.5%)
11 06 (5.6%)
12 42 (37.8%)
13 24 (21%)
14 18 (15.8%)
15 09 (7.9%)
and other animals [19, 20]. Ajayi et al. [17] determined the
antibiotic susceptibility patterns of commensal E. coli from
feces of apparently healthy cattle in Ado Ekiti, Nigeria, from
ready to slaughter cattle. Their result revealed E. coli isolates
which showed resistance to at least 3 of the eight antibiotics
tested [17]. All the isolates showing multiple antimicrobial
resistance in this study were screened for possible ESBL
production. Extended-spectrum 𝛽-lactamase indeed is a
superbug of trouble to clinicians and microbiologists and is
creating environmental stress to pharmaceutical pipeline in
the development of new antibiotics.
The Health Protection Agency of the United Kingdom
recommends testing Cefpodoxime or both Cefotaxime and
Ceftazidime as a first screening test [21]. This study revealed
the combination of the two latter drugs separated at 20mm
distance achieves 80% sensitivity to adequately detect ESBL
production, meaning that only 20% of the isolates would
need further testing. This conforms to some other studies.
Garrec et al. [22] reported a sensitivity of 77% using this same
method. Generally, evaluations of the double disc diffusion
test have revealed sensitivities of the method ranging from
79% to 97% and specificities ranging from 94% to 100%
[23, 24].The sensitivity of Cefpodoxime in this studywas 89%
while specificity was 82%.The rate of false positive prediction
(1 − specificity) was 0.18 (18%). Cefpodoxime was found to
have the highest sensitivity in this study and is thus in agree-
ment with a study by Jain and Mondal [25] who concluded
their report using the standard disc diffusion as screening
test for identifying ESBL producers that Cefpodoxime was
found to be the most efficient antimicrobial agent having
a sensitivity of 93% and a specificity of 85.7% in screening
isolates as potential ESBL producers followed by Ceftazidime
with a sensitivity of 89.6% and specificity of 80.9% and
Cefotaxime having sensitivity of 81.6% and specificity 85.7%
[25]. However, it has been reported that it is adequate to use
Cefotaxime, which is consistently susceptible to CTX-M, and
Ceftazidime, which is a consistently good substrate for TEM
and SHV variants but if only one drug is to be used, then the
single best indicator for ESBL producer has been found to be
Cefpodoxime [11, 26].
Using the Oxoid ESBL brilliance Agar, the sensitivity was
79% and specificity was 67%, while rate of false positive
prediction (1 − specificity) was 33%. This was in contrast to a
study published by Huang et al. [27], who reported a sensitiv-
ity of 94.9% and specificity of 95.7%. According to data on file
at Oxoid (http://www.oxoid.com/), the performance of this
product was rated as sensitivity having 95% and specificity
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Table 5: Association of phenotypic tests and molecular characterization of E. coli isolates from animals.
Interactions Chi square (𝜒2) Significance Degree of freedom
CEFPODOXIME/ESBL BA/DDDT/GENE 0.000 1.00 1
ESBL BA/GENES 0.000 1.000 1
CEFPODOXIME/DDST/GENE 4.961 0.026∗ 1
CEFPODOXIME/ESBL BA 17.540 <0.001∗ 1
ESBL BA/DDST 24.466 <0.001∗ 1
ESBL BA/CTX M 0.000 1.000 2
CEFPODOXIME/DDST/CTX 5.009 0.025∗ 1
ESBL BA/TEM 0.000 1.000 2
CEPODOXIME/TEM 0.165 0.684 2
DDST/TEM 22.407 <0.001∗ 1
ESBL BA/SHV 0.000 1.000 2
DDST/SHV 0.000 1.000 2
CEFPODOXIME/SHV 0.000 1.000 2
∗Statistically significant.
CEFPODOXIME: Cefpodoxime screening test.
DDST: double disc synergism test.
ESBL BA: ESBL brilliance agar screening test.
SHV: detection of SHV genes.
TEM: detection of TEM genes.
CTX-M: detection of CTX-M genes.
having 94%. The differences observed in this study could be
due to the use of already well characterized (known) ESBL
producing isolates in the evaluation as well published that any
results obtained by this method are presumptive and should
be confirmed by other methods.
Following the screening of the E. coli isolates for ESBL
genes using Polymerase Chain Reaction (PCR), 𝑏𝑙𝑎TEM was
detected in 48 (42.1%) and 𝑏𝑙𝑎CTX-M was detected in 51
(44.7%) and 𝑏𝑙𝑎SHV1 was not detected in any of the isolates.
These findings suggest that 𝑏𝑙𝑎CTX-M was more common
among the ESBL genes in these isolates which conforms to
other studies [11, 28]. In this study, the occurrence of ESBL
producing E. coli was as high as 63.2% as ESBL genes were
detected in 72 out of 114 isolates screened. This is alarming
and worrisome and higher than reports from clinical isolates
in Nigeria, class A and D ESBLs and p-AmpC were found
in hospital settings, and the prevalence ranged from 10.3 to
27.5% [6, 29–32].
Although most of these studies were done using E. coli
isolates from humans, ESBLs have been reported to be
plasmid encoded implying that these resistance determinants
are found in our environment and can be transferred from
one organism to another. The high prevalence of these ESBL
producers in fecal samples of animal further buttresses the
hypothesis that animals might become infection sources or
even reservoirs (the natural persistent source of infection)
contributing to the spread of these bacteria [9]. These resis-
tant traits call for gross surveillance in community settings
because ESBLs gene is a world growing treat for available
antibiotics but its epidemiological effect and evaluation are
still underestimated with low awareness.
In conclusion, to the best of our knowledge this is the
first report of phenotypic and molecular investigation of
bla genes (CTX, SHV, and TEM) from animal fecal samples
and epidemiological relevance of different phenotypic and
molecular methods. Multiple drug resistant ESBL producing
E. coli is present in fecal samples of cattle and pigs in Ado
Ekiti. The differences observed in the detection of ESBL
positive isolates by the three different methods may be
justified by the lower sensitivity of the phenotypic methods
and the influence of environmental factors on the incidence
of resistance.
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